Further analysis revealed that the expression of CD52 is regulated by the TGF-β/Smad3 signaling pathway, and CD52 may promote the development of T2DM by inhibiting the activation of CD52low T cells. This evidence concerns the gene SMAD3 and type 2 diabetes mellitus.